MIGS

iSTAR Medical Expands International Commercial Rollout of MINIject® with Successful First Implants Completed in Australia

Retrieved on: 
Wednesday, January 10, 2024

Australia is the first territory outside of Europe for iSTAR Medical to have progressed its commercial roll out of MINIject®, following the successful expansion into countries including Germany, the UK, Switzerland, and most recently, Ireland.

Key Points: 
  • Australia is the first territory outside of Europe for iSTAR Medical to have progressed its commercial roll out of MINIject®, following the successful expansion into countries including Germany, the UK, Switzerland, and most recently, Ireland.
  • With this expansion, glaucoma patients across Australia will now be able to benefit from MINIject®, the only commercially available supraciliary MIGS implant.
  • MINIject® has demonstrated meaningful and sustained performance, combined with a favorable safety profile, and offers a treatment option for open-angle glaucoma.
  • I would like to thank the clinicians involved for helping us achieve this significant milestone and look forward to reaching more patients throughout Australia and beyond.”

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

Retrieved on: 
Monday, January 8, 2024

MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2023.
  • The Company’s cash and cash equivalents as of December 31, 2023, was approximately $138 million, compared to $144.5 million as of September 30, 2023.
  • The Company’s fourth quarter and full year 2023 financial results are preliminary and subject to the completion of the Company’s 2023 audit.
  • The Company expects to announce complete fourth quarter and full year 2023 financial results in March 2024.

Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation

Retrieved on: 
Thursday, December 28, 2023

The Company applauds the decision which effectively retains reimbursement and full access for Medicare patients to all Iridex cyclophotocoagulation products.

Key Points: 
  • The Company applauds the decision which effectively retains reimbursement and full access for Medicare patients to all Iridex cyclophotocoagulation products.
  • By retiring the LCDs, the MACs have supported continued access to advanced patient care like MPTLT,” said David I. Bruce, President & CEO, Iridex Corporation.
  • Between October 24th, 2023 and November 9th, 2023, five of the seven MACs published LCDs targeting MIGS procedures, which also partially restricted criteria for coverage of cyclophotocoagulation reimbursement.
  • As a result, there will be no change in January 2024 to the current Medicare coverage for MIGS procedures performed with Iridex MicroPulse® TLT.

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

Retrieved on: 
Thursday, December 28, 2023

MENLO PARK, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, supports the decision announced by five Medicare Administrative Contractors (“MACs”) to withdraw their final local coverage determinations (“LCDs”) for Micro-Invasive Glaucoma Surgery (“MIGS”) that were scheduled to take effect on January 29, 2024.

Key Points: 
  • MENLO PARK, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, supports the decision announced by five Medicare Administrative Contractors (“MACs”) to withdraw their final local coverage determinations (“LCDs”) for Micro-Invasive Glaucoma Surgery (“MIGS”) that were scheduled to take effect on January 29, 2024.
  • All five MACs have now issued statements that the final LCDs will not go into effect on January 29, 2024.
  • As a result, there will be no change in January 2024 to the current Medicare coverage for MIGS procedures performed with the OMNI Surgical System.
  • Additionally, we appreciate the support from the Medical Device Manufacturers Association (MDMA) and numerous patient advocacy groups.”

iSTAR Medical continues European expansion with first MINIject® surgeries in the Netherlands

Retrieved on: 
Friday, December 22, 2023

Glaucoma is the cause of visual impairment or blindness in four percent of the total number of patients in the Netherlands1.

Key Points: 
  • Glaucoma is the cause of visual impairment or blindness in four percent of the total number of patients in the Netherlands1.
  • Patients were successfully implanted at the University Eye Clinic of the Maastricht University Medical Center+ by Prof. Henny Beckers, Head of the Glaucoma Clinic and Director of the Ophthalmology Residency Program.
  • iSTAR Medical’s rollout of MINIject® in the Netherlands adds to its existing portfolio of European countries.
  • MINIject® continues to demonstrate meaningful and sustained performance in lowering intraocular pressure (IOP) combined with a favorable safety profile.

Iridex Reports Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, November 14, 2023

MOUNTAIN VIEW, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.
  • Operating expenses for the third quarter of 2023 decreased to $7.3 million for the third quarter of 2023 compared to $8.2 million in the same period of the prior year and $8.3 million in the second quarter of 2023.
  • The decrease is the result of cost optimization efforts that began in the second quarter of 2023.
  • Cash use of $1.8 million in the third quarter increased compared to $1.2 million in the second quarter of 2023.

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

Retrieved on: 
Tuesday, November 7, 2023

Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.

Key Points: 
  • Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.
  • Achieved total gross margin of 86.6% in the third quarter of 2023 compared to 84.3% in the same period in the prior year.
  • On October 26, 2023, WPS Government Health Administrators (“WPS”), a Medicare Administrative Contractor (“MAC”), published an LCD with an effective date of December 24, 2023.
  • Sight Sciences' management team will host a conference call today, November 7, 2023, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

iSTAR Medical conducts first MINIject® surgeries in Ireland, expanding commercial rollout in Europe

Retrieved on: 
Tuesday, October 31, 2023

iSTAR Medical conducts first MINIject® surgeries in Ireland, expanding commercial rollout in Europe

Key Points: 
  • iSTAR Medical conducts first MINIject® surgeries in Ireland, expanding commercial rollout in Europe
    WAVRE, Belgium — 31 October 2023: iSTAR Medical , a medtech company delivering breakthrough eye care solutions to patients, today announces that the first patients in Ireland have been implanted with MINIject ®, expanding the commercial rollout of the Company’s minimally-invasive glaucoma surgery (MIGS) device across Europe.
  • Currently the only commercially available supraciliary MIGS implant, MINIject® has demonstrated meaningful and sustained performance, combined with a favorable safety profile.
  • The continuation of our commercial rollout of MINIject® with the recent implantations in Ireland represents iSTAR Medical’s mission to preserve the vision of glaucoma patients around the world.
  • As we continue with our global expansion, we look forward to making MINIject® more widely available to patients.”

Hexiris Pharma Welcomes World-Renowned Ophthalmologist Dr. Ike Ahmed to its Scientific Committee

Retrieved on: 
Monday, October 30, 2023

DIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.

Key Points: 
  • DIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.
  • “We are truly honoured that Dr. Ahmed has agreed to join Hexiris Pharma’s Scientific Committee,” said Dr. Nir Shoham-Hazon, Co-Founder and Co-CEO of Hexiris Pharma.
  • I’m pleased to be joining the Scientific Committee at Hexiris Pharma and join in the important work of improving the lives of patients and bringing new solutions and opportunities to ophthalmologists,” said Dr. Ahmed.
  • He has given over 750 scientific presentations thus far in his career, including 31 visiting professor’s lectures around the world.

Iantrek reports two upcoming American Academy of Ophthalmology presentations of its breakthrough glaucoma surgical technologies, including 1-year results of a novel supraciliary outflow micro-interventional procedure

Retrieved on: 
Monday, October 16, 2023

These presentations will highlight the clinical results of its CycloPen supraciliary interventional system for suprachoroidal outflow bio-tissue reinforcement as well as a combined dual-outflow trabecular and supraciliary intervention in Open Angle Glaucoma.

Key Points: 
  • These presentations will highlight the clinical results of its CycloPen supraciliary interventional system for suprachoroidal outflow bio-tissue reinforcement as well as a combined dual-outflow trabecular and supraciliary intervention in Open Angle Glaucoma.
  • Iantrek continues to validate its innovative MIGS technologies for supraciliary and trabecular outflow enhancement.
  • Iantrek’s second presentation reports on a novel combination MIGS intervention to address both the suprachoroidal and the trabecular outflow.
  • Iantrek is developing several next-generation MIGS technologies for dual-outflow enhancement utilizing advanced supraciliary, trabecular and bio-tissue µ-interventions.